CYTK Stock — Cytokinetics Incorporated: Cash, EV, Pipeline

Share price

$68.78

Market cap

$9,562.0M

Cash

$1,165.7M

Enterprise value

$8,644.5M

Balance sheet

Cash	$1,165.7M
Debt	$248.2M
Net cash	$917.5M
Enterprise value	$8,644.5M
Basic shares	0.1M shares
Fully diluted shares	172.3M shares
Fully diluted market cap	$11,849.3M
Cash per share	$11,657.00

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CYTK daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 24, 2026	Aficamten	Phase 3	Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy	—
Oct 13 - Nov 24	CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)	Phase 2	Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)	—
Oct 13 - Nov 24	Omecamtiv Mecarbil (OM)	Phase 3	Heart Failure; Heart Failure With Reduced Ejection Fraction	—
Apr 12 - May 24	Aficamten (5 - 20 mg)	Phase 3	Symptomatic Hypertrophic Cardiomyopathy (HCM)	—
Feb 12 - Mar 26	Aficamten	Phase 3	Pediatric; Symptomatic Obstructive Hypertrophic Cardiomyopathy	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Aficamten

Approved · Active Modality: small molecule (oral; allosteric reversible inhibitor)

Aliases MYQORZO

Target cardiac myosin

Partnerships Sanofi: exclusive license for China and Taiwan (up to $160M milestones in oHCM/nHCM; tiered royalties low-to-high teens); Bayer: Japan license (milestones for first Phase 3 dosing in Japan achieved 2025)

Indications

obstructive hypertrophic cardiomyopathy (oHCM, symptomatic) (Approved)
non-obstructive hypertrophic cardiomyopathy (nHCM) (Phase 3)
pediatric oHCM (Stage not disclosed)

Catalysts

— fourth quarter of 2026
— fourth quarter of 2026

Status note First commercial product: FDA approved December 2025, EC February 2026, NMPA December 2025, UK MHRA July 2026 for symptomatic oHCM; REMS required (heart failure/systolic dysfunction risk). Ongoing: ACACIA-HCM Phase 3 in nHCM, CEDAR-HCM pediatric oHCM, FOREST-HCM open-label extension; supplemental NDA (MAPLE-HCM vs metoprolol) submitted January 2026.

Omecamtiv mecarbil

Phase 3 · Active Modality: small molecule (cardiac myosin activator)

Target cardiac myosin

Partnerships Amgen: collaboration (conducted GALACTIC-HF Phase 3); Corxel Pharmaceuticals (formerly Ji Xing): exclusive license for China and Taiwan; Royalty Pharma: revenue interest financing

Indications

heart failure with severely reduced ejection fraction (HFrEF) (Phase 3)

Status note GALACTIC-HF Phase 3 cardiovascular outcomes trial conducted by Amgen; additional confirmatory Phase 3 (COMET-HF) referenced as basis for potential future approvals.

Ulacamten

Phase 2 · Active Modality: small molecule (oral; cardiac myosin inhibitor)

Aliases CK-586

Target cardiac myosin

Partnerships Royalty Pharma: revenue participation right

Indications

heart failure with preserved ejection fraction (HFpEF, symptomatic, hypercontractility/ventricular hypertrophy subgroup) (Phase 2)

Status note Selective cardiac myosin inhibitor to reduce hypercontractility in HFpEF; Phase 1 completed, Phase 2 dose-finding in HFpEF patients with LVEF ≥60%.

CK-089

Phase 1 · Active Modality: small molecule (oral)

Target skeletal muscle troponin

Indications

muscular dystrophy (specific type) (Phase 1)

Status note Fast skeletal muscle troponin activator; Phase 1 single/multiple ascending dose study in healthy participants (first dosed Q4 2024). FDA partial clinical hold limits dosing at exposures above certain levels, which may limit therapeutic-dose identification. Emerging neuromuscular pipeline beyond CK-089 has no distinct candidate named.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Omecamtiv Mecarbil (OM)
Lead indication	Heart Failure
Lead phase	Phase 3
Active trials	5
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06736574	Phase 3	Recruiting	Sponsor	CYTK	—	Heart Failure; Heart Failure With Reduced Ejection Fraction	—
NCT04848506	Phase 3	Enrolling by invitation	Sponsor	CYTK	—	Symptomatic Hypertrophic Cardiomyopathy (HCM)	—
NCT06412666	Phase 3	Active, not recruiting	Sponsor	CYTK	—	Pediatric; Symptomatic Obstructive Hypertrophic Cardiomyopathy	—
NCT06081894	Phase 3	Active, not recruiting	Sponsor	CYTK	SNY	Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy	—
NCT06793371	Phase 2	Recruiting	Sponsor	CYTK	—	Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)	—
NCT07600177	Not disclosed	Recruiting	Collaborator	Oregon Health and Science University	—	Hypertrophic Cardiomyopathy (HCM)	—
NCT07054073	Not disclosed	Recruiting	Collaborator	Christopher Kramer	—	Hypertrophic Cardiomyopathy (HCM)	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 7 active trials for Cytokinetics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	2,862,003	+140,845	2.08%	2026-08-14
Frazier Life Sciences	1,159,879	no change	2.15%	2026-08-14
ADAR1 Capital Management	457,907	-174,649	1.83%	2026-08-14
Sphera Biotech	219,987	+180,170	2.68%	2026-08-14
Baker Bros. Advisors	211,267	+211,267	0.09%	2026-08-14
OrbiMed Advisors	25,800	+25,800	0.04%	2026-08-14
Logos Global Management	0	-875,000	0.00%	2026-08-14
Ikarian Capital	0	-283,572	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CYTK — Cytokinetics Incorporated

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders